Regulators and Experts Debate AI Regulation in Healthcare
-
The FDA does not require understanding a drug's mechanism of action for approval, raising questions around regulating AI models in healthcare.
-
The event hosted discussions between regulators, faculty, and industry experts on regulating AI in healthcare.
-
Attendees debated controversial opinions on AI regulation under Chatham House Rule for anonymity.
-
Speakers emphasized issues like healthcare labor shortages, AI deployment priorities, education gaps around AI, and lack of quality datasets.
-
By the end, attendees suggested continuing the productive closed-door discussions to keep regulators updated on AI developments.